Articles tagged with Memory T Cells
Researchers have discovered that T follicular helper cells can persist for at least 400 days after infection, supporting antibody production even in late stages. This finding opens up new prospects for creating long-term acquired immunity through vaccination strategies.
A new study from Penn researchers reveals that the molecular mechanisms of newly formed precursor T cells drive transformation into exhausted T cells. The discovery could help identify patients who may benefit from specific treatments, such as checkpoint inhibitors.
The study found that almost complete immune capacity in the gut had developed as early as 14 weeks, with cells from both innate and adaptive immune systems present. This discovery could lead to the development of new maternal vaccines and a better understanding of the risk of autoimmune diseases.
Researchers found that patients with non-small cell lung cancer who develop checkpoint inhibitor pneumonitis have higher levels of memory T cells in their lungs compared to those without the condition. The study also identified decreased levels of regulatory T cells, which may lead to new ways to treat this complication.
Researchers found that memory T cells in bone marrow enriched with fat tissue protected mice from bacterial infections and tumors when fed restricted diets. The study suggests how the immune system may have evolved to survive limited food availability.
Research found that T-cells dominate advanced plaques and a subtype of T-cells, called CD4-positive effector memory cells, are more common in patients who have previously had a stroke or mini-stroke. This localized inflammation may be targeted by new immune therapies to reduce heart attack and stroke risk.
A Monash University study reveals how helper T cells aid memory T cells in optimal functioning and generate a robust response against infection. The research sheds light on the mechanisms behind immunological memory and its potential applications in creating new vaccines and treatments for diseases.
This special issue of Viral Immunology delves into the intricacies of viral brain infection, focusing on immune responses such as IFNα/ß signaling and chemokine CXCL10. Research reveals the importance of astrocytes, brain-resident memory T-cells, and chemokines in protecting against encephalitic viruses.
A triple combination regimen including adoptive T cell therapy, a PIM kinase inhibitor, and a PD-1 inhibitor boosts T cell persistence and improves survival in a mouse model of melanoma. This treatment doubles the migration of anti-tumor T cells to the tumor site and quadruples survival compared to ACT alone.
Researchers identified specific CD8 T cell states associated with patient response to checkpoint immunotherapy for melanoma. The study found that tumors responding to therapy had a higher proportion of stem-cell-like memory CD8 T cells, while non-responding tumors had more dysfunctional/exhausted T cells.
Exposure to malaria during pregnancy can trigger an immune response in the fetus, leading to higher levels of memory T cells and reduced clinical malaria incidence in childhood. Infants born to mothers with placental malaria have a lower risk of contracting malaria as children.
Researchers discovered that non-circulating memory T cells offer optimal protection against Salmonella infection, leading to the development of more effective and safe vaccines. The study's findings have significant implications for addressing enteric fever and invasive non-typhoidal Salmonellosis in resource-poor communities.
Researchers at Gladstone Institutes discovered how to improve the survival of CD8 T cells, which can combat tumors and chronic infections. The study found that deleting two specific molecules enhances the survival of effector cells and yields more protective memory cells.
Researchers found targeting resident memory T cells restores pigmentation in mouse model of vitiligo, offering potential new treatment. Current treatments can restore color but depigmentation recurs in up to 40% of cases.
The NIH has awarded a $2 million grant to Ken Oestreich at the Virginia Tech Carilion Research Institute to study immunological memory. The research aims to understand how immune cells form and transition into memory cells, which can recognize and respond to pathogens more efficiently.
Researchers at Cornell University have discovered that fetal T cells persist into adulthood and play a crucial role in fighting infection. These fast-acting immune cells can provide broad protection against pathogens and are activated faster than adult cells.
A Monash University study found that older people's reduced immune responses to cancer and vaccines are due to the accumulation of dysfunctional immune cells. The researchers discovered two types of T cells that lose their ability to fight diseases with age, leading to lower success rates for cancer immunotherapy in the elderly.
Researchers identified a subset of healthier T cells, marked by CD8 and CD27 expression, that correlate with clinical responses in CLL patients. The findings suggest a new patient-selection tool for CAR T cell therapy and potential improvements through emerging cell manufacturing techniques.
Researchers found that a transcription factor protein called Runx3 plays a critical role in directing T cells towards memory cells, which can live for decades. This discovery may lead to the development of drugs that improve immune responses to vaccines and treatments for chronic diseases such as cancer.
Researchers found that combining anti-CTLA-4 and anti-PD-1 immunotherapies enhances response rates and generates more memory T cells, leading to better tumor control. This combination may help prevent relapse in patients with therapies targeting CTLA-4 and PD-1 checkpoints.
A study led by UC Berkeley researchers found that a small pool of immune cells remain alive for years after vaccination, developing unique features such as methylation patterns to keep them primed and ready to respond to the same microbe. This discovery may help scientists develop better vaccines and understand differences among diseases.
Research reveals memory CD8 T cells arise from effector CD8 T cells, which undergo demethylation to express genes associated with naïve T cells. This finding provides insight into designing more effective vaccines and expanding cancer immunotherapies.
Researchers found that memory T cells retain an 'epigenetic signature' from their effector state, allowing them to rapidly respond to future threats. This breakthrough has significant implications for vaccine development and could aid efforts to eliminate HIV from the body.
A study published in mBio reveals a strong connection between the onset and severity of acute infectious mononucleosis (mono or 'kissing disease') and the T-cell population, specifically those that react to both EBV and influenza A virus. Individuals with severe cases of mono have higher levels of cross-reactive T-cells, while those wi...
Scientists at Boston Children's Hospital have identified the molecule responsible for releasing interleukin-1 (IL-1) from immune cells. The study found that gasdermin D enables IL-1 release without killing the cell, which could lead to more potent and long-lasting vaccines.
Researchers identified specific immune memory T-cells as the site where HIV hides to evade detection, revealing a key target for future therapies. This discovery provides new insights into the chronic illness and offers potential avenues for developing a cure.
Researchers have discovered a way to activate the proteasome in CD8+ T cells, generating more long-lived memory cells that can provide lifelong protection. This approach could be used as an adjuvant therapy to enhance vaccine and immunotherapy effectiveness.
A recent study reveals that innate lymphoid cells (ILCs) compete with T cells for a shared source of interleukin-7 (IL-7), a protein essential for their survival. This competition sheds light on the complex phenomenon of homeostasis, which supports the long-term survival of immune cells.
Researchers found that generating an optimal immune response against cancer requires the cooperation of two types of memory T cells: those that circulate in the blood and those that reside in tissues. This discovery has the potential to improve current cancer immunotherapy strategies, especially in preventing metastasis.
Researchers have identified a key to generating effective tissue-resident memory T cells that can fight off infections in organs. By adjusting the strength of T cell receptor stimulation, scientists can promote the generation of these cells, which could lead to more efficient protection against viruses like Zika and HIV.
Researchers found that patients with high ICOS expression had improved survival, while those with low CD28 expression had poor outcomes. The study suggests that these biomarkers may help clinicians identify IPF patients at greatest risk and develop early intervention strategies.
A team of researchers identified the CD103 molecule as crucial for the long-term residence and potent anti-tumor response of T cells in the skin. This finding supplements a previous discovery that T cells residing in the skin are responsible for a strong protective response against melanoma.
A new study by Dartmouth researchers reveals that resident memory T cells reside in the skin, where they can quickly eliminate melanoma cells. This finding suggests that these immune cells play a crucial role in protecting against future tumors and may serve as a target for future cancer therapies.
A new study has identified a critical molecular mechanism that operates in memory T cells, which could be manipulated to produce and maintain more memory T cells. This finding could lead to improved vaccinations and cancer immunotherapies by enhancing the production of memory T cells.
Researchers identify genes involved in lipid uptake as critical for TRM cell function, revealing a key dependency on fatty acids. Targeting these lipids could enable selective removal of TRM cells, offering new therapeutic opportunities for autoimmune diseases.
A new study identifies Gamma Delta T cells as adaptable immune cells with immunological memory against previous infections and cancerous targets. This finding challenges traditional views of these cells as 'natural born killers' and presents opportunities for developing new cell therapies and vaccines.
Activated T-cells play a crucial role in promoting heart failure after a heart attack by attacking heart muscle tissue. Targeting specific T-cell subsets at defined stages of disease may represent a better therapeutic approach to improve heart failure outcomes.
LJI researchers identified key factors controlling T cell fate, shedding light on molecular mechanisms behind T cell exhaustion. This study offers new approaches to clinical intervention strategies to modulate T cell activity and improve immune function.
Australian researchers discovered that immune T cells develop in 'families' programmed to divide and die at different times after an infection is detected. This understanding may underpin future improvements in vaccination and the treatment of autoimmune diseases.
Researchers found that exhausted T cells, which are supposed to fight cancer, have a distinct epigenetic profile that prevents them from becoming durable memory cells. This limits the effectiveness of checkpoint inhibitors, which temporarily boost their activity but don't lead to long-lasting benefits.
Research by Institute for Basic Science reveals that aging compromises the survival of naïve T cells by degrading the supportive environment within the lymph nodes. The study found that the production of a key protein responsible for attracting T cells to the lymph nodes declined with age, resulting in reduced effective immune response.
Studies in mice reveal that uneven mTORC1 activity reprograms daughter T cells, producing active killer cells and memory T cells. This asymmetric partitioning may have implications for understanding stem cell differentiation and development across biological systems.
Researchers at Boston Children's Hospital found a fatty chemical called oxPAPC that induces an immune response in mice, causing T-cells to become highly active and effective. This discovery could lead to the development of more effective vaccines against various infections.
Recent advances in T cell therapy have brought the idea of fighting chronic infections and cancers closer to reality. The use of potent cells with a safety mechanism has been demonstrated, and clinical trials have yielded highly promising results.
Researchers found that younger T cells are critically important in T cell immunotherapy and can be more effective when collected earlier. This discovery has the potential to change clinical management in T cell immunotherapy.
Researchers have found that MHC class II molecules on graft endothelial cells activate CD4+ effector memory T cells, which then promote the development of graft-targeting CD8+ cytotoxic T cells. This interaction can be blocked to limit acute rejection in organ transplants.
The new method allows tracking of gene expression changes in stem cells, immune cells, and potential applications for cancer research. Researchers discovered unique family-specific transcriptional profiles for single T cells, shedding light on how a single founding cell gives rise to diverse progeny.
Researchers have discovered that cytomegalovirus activates the immune system to continually feed sentinel cells into mucous membranes, offering better and more immediate protection. This finding suggests a strong candidate for vaccines against various pathogens, including HIV and tuberculosis.
Helper T cell proteins Oct1 and OCA-B work together to put immune response genes on standby, allowing for rapid activation upon re-exposure. This study sheds light on the molecular mechanisms controlling immunological memory in CD4+ cells.
Researchers propose that deep sleep strengthens immunological memories of previously encountered pathogens, enabling adaptive responses. Studies show that slow-wave sleep contributes to the formation of long-term memories of abstract information.
Researchers found that memory T cells specific to parasite infections can form in the skin, setting up a defense against future infections. This discovery could inform efforts to develop an effective vaccine for leishmaniasis and other diseases like tuberculosis and leprosy.
Researchers discovered that memory CD4+ T cells linger in the skin for up to a year after resolving Leishmania infection. These skin-resident memory cells help reduce parasite numbers during secondary infections by recruiting blood-borne memory cells, suggesting a new approach to developing anti-Leishmania vaccines.
Researchers found that regulatory T cells suppress killer T cells through a protein on their surface, enabling the immune system to remember past pathogens. This discovery could lead to faster-acting vaccines and improved immunity to diseases like cancer.
Researchers have created a detailed atlas of surface proteins on naive CD4+ T cells, which play a crucial role in the development of immunological memory. The findings provide insights into the cell's maturation process and could lead to new therapeutic approaches for allergies and asthma.
Researchers have developed a new therapy using naïve cells to prevent cytomegalovirus, Epstein-Barr virus, and adenovirus infections in cord blood transplant patients. The treatment has shown safety and efficacy in clinical trials.
Researchers identify 'Follicular Memory T cells' near lymph node entrances to screen for microbe re-entry. These cells help create potent antibodies in secondary antibody responses, outsmarting circulating memory cells. This discovery paves the way for more effective vaccines.
Researchers at CRT and Bioinvent are developing antibodies targeting OX40 and 4-1BB, 'co-receptors' that stimulate killer T-cells. The goal is to reverse tumour cell suppression of immune responses, allowing the immune system to fight cancer.
A study published in the Journal of Immunology found that infusing memory cells can produce and repeatedly replenish all of the T-effector cells needed to fight CMV infection. This approach may improve on current therapeutic options for controlling CMV infection, which affects up to 80% of adults in the US.
Scientists successfully killed HIV-infected cells using a new technique that boosts killer T-cell response. The method could be used as part of an HIV cure strategy by awakening latent immune cells and generating an immune response.
Researchers found that memory cells arise directly from effector cells through a signaling molecule called Bcl-6. This discovery could lead to more effective vaccine development by strengthening the immune system's ability to respond to recurring pathogens.